28 Nov 2012 08:33
28 November 2012
Directors' dealings
In a crossed trade today through N+1 Singer, ACP IV LP sold its entire position of ordinary shares to directors and other investors including one significant shareholder. Non-executive director David Mack is a director of Alta Partners, which manages ACP IV LP. The agreed price is 2.5p, which matches the £5m subscription announced earlier today 28 November 2012.
| Number of ordinary shares bought |
| Total shareholding after transaction and loan conversion* | % holding post transaction |
Robert Keith | 20,000,000 | Significant shareholder | 488,325,844 | 26.11% |
Ali Mortazavi | 2,400,000 | Director | 82,400,000 | 4.41% |
Jerry Randall | 1,600,000 | Director | 2,220,000 | 0.12% |
Tim Freeborn | 200,000 | Director | 200,000 | 0.01% |
Others | 1,156,422 |
|
|
|
Total | 25,356,422 |
|
|
|
*after converting £1m loan note into 200m shares
Silence Therapeutics
Ali Mortazavi, director of corporate strategy Tim Freeborn, finance director +44 20 7491 6520 a.mortazavi@silence-therapeutics.com t.freeborn@silence-therapeutics.com
| Nplus1 Singer
Shaun Dobson +44 20 7496 3000 shaun.dobson@n1singer.com
|
Notes for editors
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.
The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™.
The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has laboratories in Berlin and is headquartered in London.